GFB-887(TRPC5通道抑制剂)在FSGS、难治性MCD或糖尿病肾病中的安全性与疗效:TRACTION-2试验设计
TRACTION-2是一项2a期、双盲、安慰剂对照、多剂量递增研究,评估GFB-887在局灶节段性肾小球硬化(FSGS)、难治性微小病变(TR-MCD)或糖尿病肾病(DN)患者中的安全性和疗效。主要目的是评估递增剂量GFB-887对蛋白尿的影响,并探索尿Rac1作为预测生物标志物的价值。预计样本量在FSGS/TR-MCD中检测54%、在DN中检测44%的蛋白尿治疗差异具有80%把握度。
要点
- GFB-887是靶向足细胞的TRPC5小分子抑制剂,旨在抑制TRPC5-Rac1通路过度激活。
- TRACTION-2纳入FSGS、TR-MCD或DN患者,随机接受3个递增剂量GFB-887或安慰剂治疗12周。
- 主要终点为蛋白尿变化,同时评估安全性、生活质量、PK/PD及尿Rac1与疗效的关联。
核心结论
- TRACTION-2将探索GFB-887靶向阻断TRPC5-Rac1通路对FSGS、TR-MCD和DN患者是否有效且安全,并评估尿Rac1作为治疗反应预测生物标志物的潜在价值。
研究设计与样本
- TRACTION-2是一项2a期、双盲、安慰剂对照、多剂量递增研究(NCT04387448)。
- 纳入正在接受稳定肾素-血管紧张素系统阻断和/或免疫抑制治疗且持续蛋白尿的成人FSGS、TR-MCD或DN患者。
- 患者随机分配至3个递增剂量水平的GFB-887或安慰剂组,治疗12周。
- 根据适应性中期分析结果,队列可能扩展或进行生物标志物富集。
主要发现
- 首次人体研究表明GFB-887安全且耐受性良好,药代动力学特征支持每日一次给药,并在健康成人中剂量依赖性降低尿Rac1。
关键数值与推荐
- 主要目的是评估递增剂量GFB-887对蛋白尿的影响。
- 预计样本量在FSGS/TR-MCD中检测54%、在DN中检测44%的蛋白尿治疗差异(对比安慰剂)具有80%把握度。
临床怎么用
- TRACTION-2为GFB-887在FSGS、TR-MCD和DN中的后续疗效和安全性研究提供设计框架。
- 尿Rac1可能作为预测GFB-887治疗反应的生物标志物,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: A critical unmet need exists for precision therapies for chronic kidney disease. GFB-887 is a podocyte-targeting, small molecule inhibitor of transient receptor potential canonical-5 (TRPC5) designed specifically to treat patients with glomerular kidney diseases characterized by an overactivation of the TRPC5-Rac1 pathway. In a first-in-human study, GFB-887 was found to be safe and well tolerated, had a pharmacokinetic (PK) profile allowing once-daily dosing, and dose dependently decreased urinary Rac1 in healthy adults. METHODS: TRACTION-2 is a phase 2a, double-blind, placebo-controlled, multiple-ascending dose study of GFB-887 in patients with focal segmental glomerulosclerosis (FSGS), treatment-resistant minimal change disease (TR-MCD), or diabetic nephropathy (DN) (NCT04387448). Adult patients on stable renin-angiotensin system blockade and/or immunosuppression with persistent proteinuria will be randomized and dosed in 3 ascending dose levels to GFB-887 or placebo for 12 weeks. Cohorts may be expanded or biomarker-enriched depending upon results of an adaptive interim analysis. RESULTS: The primary objective is to evaluate the effect of increasing doses of GFB-887 on proteinuria. Safety and tolerability, quality of life, pharmacokinetic/pharmacodynamic profiles, and the potential association of urinary Rac1 with efficacy will also be evaluated. The projected sample size has 80% power to detect a treatment difference in proteinuria of 54% (FSGS/TR-MCD) or 44% (DN) compared to placebo. CONCLUSION: TRACTION-2 will explore whether targeted blockade of the TRPC5-Rac1 pathway with GFB-887 is an efficacious and safe treatment strategy for patients with FSGS, TR-MCD, and DN and the potential value of urinary Rac1 as a predictive biomarker of treatment response.
引用
- Walsh L, Reilly JF, Cornwall C, et al. Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design. Kidney Int Rep. 2021. PMID: 34622097. doi:10.1016/j.ekir.2021.07.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。